Glioma, Radiomics, Transcriptomics
Conditions
Brief summary
This project intends to use multiple types of biological samples from glioma patients and mouse intracranial tumor models as research objects, and comprehensively apply a series of omics sequencing technologies and molecular biology technologies to jointly define the following research objectives :
Detailed description
1. Through high-throughput sequencing technologies such as， genome sequencing, transcriptome sequencing and single-cell sequencing, Proteomics，Metabonomics and Metagenomics， the similarities and differences of the glioma immune microenvironment within and between individuals were revealed from the multi-dimensional and big data level, and the immune molecular typing of glioma was established. 2. Establish and verify that the neoantigen polypeptides predicted by AI algorithm after analyzing multi-omics data (genome, transcriptome, etc.) have good killing effect on individual tumor cells. 3. To establish an intelligent evaluation model of glioma immunotyping by integrating imaging, pathology, high-throughput sequencing data and other omics information, and to provide a visual tool for monitoring changes in the intratumoral microenvironment of glioma patients, with the expectation of helping timely intervention of immunotherapy in patients with recurrence.
Interventions
PROCEDUREsurgery
surgery
Sponsors
Yu Yao, MD
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* The patients with glioma in the Department of Neurosurgery of Huashan Hospital Affiliated to Fudan University who meet the following three conditions can be enrolled 1. They were 18-80 years old, male and female; 2. The pathological diagnosis was glioma; 3. On the basis of not affecting the clinical routine diagnosis, tissue (6 mm \* 6 mm) or paraffin section (5 pieces) can be used for research; 4. Sign informed consent or ethics committee approval
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival（OS），month | 24 month | Survival time from surgery to death in 120 patients with glioma. |
| Progress Free Survival （PFS），month | 24 month | Survival time from surgery to first progression or death from any cause in patients with glioma. |
| Tumor Mutation Burden（TMB），mutations/mb, drived from Genomic sequencing | 24 month | the level of gene mutation，including TERT、GMEM、IDH.etc. |
| Reads Per Kilobase Million（RPKM），KB^(-1), drived from Transcriptome sequencing | 24 month | the expression level of RNA,including mRNA、 miRNA、circRNA.etc |
| expression level of protein , drived from Protein sequencing | 24 month | the expression level of protein, post-translational modification and protein-protein interaction，including PD1、PDL1、CD4、CD8.etc. |
| expression level of low molecular weight protein，drived from Metabonomics | 24 month | the expression level and interaction of different Metabolites，including D-2-Hydroxyglutarate. etc. |
| expression level of DNA，drived from Metagenomics | 24 month | Differences about DNA expression of all microorganisms in the environment |
| frequency of TCR/BCR clone，drived from Immunomics | 24month | different expression level and interaction of Immune molecules，including TCR、BCR、antibody.etc. |
| expression level of protein，drived from paraffin-embedded specimens， retrospectively collected. | 24month | different expression level of proteins in Gliomas with different grades and molecular subgroups (1000 cases) |
Countries
China
Outcome results
None listed